Finoriq research workspace
Camp4 Therapeutics Corp (CAMP) Institutional Holdings & 13F Ownership
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers. Review CAMP institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Company
- Camp4 Therapeutics Corp (CAMP)
- Ticker
- CAMP
- Market Cap
- $173.2M
- Latest Price
- $3.335
- Industry
- Unclassified
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.